Moderna, Inc. announced that it is expanding its manufacturing in the U.S. by bringing the production of its drug products to its existing Moderna Technology Center (MTC) in Norwood, Massachusetts. This means that Moderna will now be able to make its mRNA medicines completely in the U.S., from start to finish. This is a big step in strengthening the company’s manufacturing operations in the U.S. and ensuring they can produce both commercial and clinical supplies of their medicines here.
This expansion shows that Moderna is continuing to invest in U.S.-based facilities. They are working to build a strong local manufacturing platform to support their growing range of mRNA vaccines and treatments. Moderna’s mRNA technology, which became well-known during its work with the U.S. government on Operation Warp Speed, is being used to explore new treatments for diseases like infections, cancer, rare diseases, and autoimmune conditions.
Construction at the MTC is already underway, and Moderna expects to finish the new drug manufacturing facility by the first half of 2027.
Moderna is a leader in mRNA medicine, a new type of treatment. The company is using its advanced technology to change the way medicines are made, with the goal of improving how we treat and prevent diseases. Since it was founded, Moderna has used its mRNA platform to develop vaccines and treatments for diseases like infections, cancer, rare conditions, and more.
Executive Statement
According to Stéphane Bancel, Chief Executive Officer of Moderna, by onshoring Drug Product manufacturing to their campus in Norwood, Massachusetts, they have completed the full manufacturing loop under one roof in the U.S. As an American company committed to building and producing in America, they are proud to strengthen their domestic footprint while bringing meaningful new jobs to the community.
